ERBB2 and breast carcinoma: This combination therapy has shown promise in overcoming resistance to anti-ERBB2 monotherapy in HER2+ breast cancer (Fujimoto et al., 2020), and ERBB2 has been identified as a key biomarker associated with synergistic responses to this combination in the AZS DREAM Challenge study (Menden et al., 2019).